Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies. Issue 12 (1st December 2016)

• Record Type: Journal Article
• Authors: Samineni, Divya; Girish, Sandhya; Li, Chunze
• Is Part Of: Expert review of clinical pharmacology. Volume 9:Issue 12(2016)
• Page Start: 1557
• Page End: 1569
• Publication Date: 2016-12-01
• Subjects: Monoclonal antibodies -- shed antigens -- soluble targets -- PK/PD modeling -- bioanalytical assays; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2016.1243055
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction: Suboptimal treatment for monoclonal antibodies (mAbs) directed against endogenous circulating soluble targets and the shed extracellular domains (ECD) of the membrane-bound targets is an important clinical concern due to the potential impact of mAbs on the in vivo efficacy and safety. Consequently, there are considerable challenges in the determination of an optimal dose and/or dosing regimen. Areas covered: This review outlines the impact of shed antigen targets from membrane-bound proteins and soluble targets on the PK and/or PD of therapeutic mAbs that have been approved in the last decade. We discuss various bioanalytical techniques that have facilitated the interpretation of the PK/PD properties of therapeutic mAbs and also considered the factors that may impact such measurements. Quantitative approaches include target-mediated PK models and bi- or tri-molecular interaction PK/PD models that describe the relationships between the antibody PK and the ensuing effects on PD biomarkers, to facilitate the mAb PK/PD characterization. Expert commentary: The proper interpretation of PK/PD relationships through the integrated PK/PD modeling and bioanalytical strategy facilitates a mechanistic understanding of the disease processes and dosing regimen optimization, thereby offering insights into developing effective therapeutic regimens. This review provides an overview of the impact of soluble targets or shed ECD on mAb PK/PD properties. We provide examples of quantitative approaches that facilitate the characterization of mAb PK/PD characteristics and their corresponding bioanalytical strategies.